Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.

颅内 D-2-羟基戊二酸作为 IDH 突变胶质瘤的监测生物标志物。

基本信息

  • 批准号:
    10358421
  • 负责人:
  • 金额:
    $ 39.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-15 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

ABSTRACT IDH-mutant gliomas are the most common gliomas of young adults. Despite initial sensitivity to chemotherapy and radiation, they invariably progress as treatment resistant lesions to become ultimately fatal. The unique metabolic phenotype of IDH-mutant glioma leaves malignant cells potentially vulnerable to several candidate therapies or therapeutic combination. There remains an urgent unmet need for a reliable quantitative monitoring biomarker to accelerate translational progress Since disease course frequently extends over several years, patient-centric models of therapeutic discovery could leverage reliable surrogate outcomes toward iterative refinement of individualized therapies. This project utilizes a phased, milestone-driven feasibility, discovery (R61; Aims 1-2) and validation analysis (R33; Aims 3-4) of D2-HG as a candidate biomarker of IDH-mutant glioma. This study takes advantage of neurosurgical access to the CNS, wherein CSF access devices utilized for clinical management may be deployed for longitudinal CSF access as an adjunct to lumbar puncture. Moreover, it utilizes tumor-based benchmarks for D2-HG content and production within the tumor based on analysis of tumor tissue and microdialysate. We hypothesize that CSF D2-HG represents a useful monitoring biomarker for IDH- mutant glioma to help quantify response to therapy and identify disease recurrence. To test this hypothesis, we propose the following aims: Aim 1: Determine the technical and biological performance characteristics of CSF D2-HG as a biomarker of IDH-mutant glioma. Detailed and rigorous analyses will be performed for D2-HG and its mass spectroscopy assay including stability, precision, accuracy, interference, and technical as well as biological variance upon repeated measurements and correlates to tumor properties based upon gold-standard benchmarks. Aim 2: Determine a baseline threshold value of CSF D2-HG diagnostic for IDH-mutant glioma and define the minimal percent change indicative of altered disease burden. Appropriate ROC models will be built with and AUC analysis to define a threshold diagnostic of IDH-mutant glioma. Cross-sectional patient cohorts will be used to evaluate responsiveness of D2HG to therapy and disease progression Aim 3: Validate CSF D2HG as a biomarker of therapeutic response. CSF D2-HG will be evaluated longitudinally in to validate responsiveness to therapy as benchmarked modified RANO criteria. Aim 4: Evaluate CSF D2HG as a biomarker of disease progression. A cumulative cross-sectional cohort of patients with verified IDH-mutant gliomas will be followed longitudinally during disease monitoring for recurrent disease to validate the defined threshold indicative of disease progression.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Terry Burns其他文献

Terry Burns的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Terry Burns', 18)}}的其他基金

Glioma intelligence from behind enemy lines
来自敌后的神经胶质瘤情报
  • 批准号:
    10566235
  • 财政年份:
    2023
  • 资助金额:
    $ 39.75万
  • 项目类别:
Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma.
颅内 D-2-羟基戊二酸作为 IDH 突变胶质瘤的监测生物标志物。
  • 批准号:
    10591511
  • 财政年份:
    2022
  • 资助金额:
    $ 39.75万
  • 项目类别:

相似海外基金

Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1998
  • 财政年份:
    2001
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1998
  • 财政年份:
    2000
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1998
  • 财政年份:
    1999
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1998
  • 财政年份:
    1998
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1994
  • 财政年份:
    1997
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1994
  • 财政年份:
    1996
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1994
  • 财政年份:
    1995
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of bacterial PCB degradation pathways
细菌 PCB 降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1994
  • 财政年份:
    1994
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of PCB degrada-tion pathways
PCB降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1991
  • 财政年份:
    1993
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
Biochemical, genetics and molecular biological studies of PCB degrada-tion pathways
PCB降解途径的生化、遗传学和分子生物学研究
  • 批准号:
    39579-1991
  • 财政年份:
    1992
  • 资助金额:
    $ 39.75万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了